130 related articles for article (PubMed ID: 32554513)
1. Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.
Zeidner JF
Clin Cancer Res; 2020 Aug; 26(16):4174-4176. PubMed ID: 32554513
[TBL] [Abstract][Full Text] [Related]
2. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
[TBL] [Abstract][Full Text] [Related]
3. Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.
Fathi AT; DiNardo CD; Kline I; Kenvin L; Gupta I; Attar EC; Stein EM; de Botton S;
JAMA Oncol; 2018 Aug; 4(8):1106-1110. PubMed ID: 29346478
[TBL] [Abstract][Full Text] [Related]
4. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
5. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
[TBL] [Abstract][Full Text] [Related]
7.
Babakhanlou R; DiNardo C; Borthakur G
Leuk Lymphoma; 2023; 64(11):1733-1741. PubMed ID: 37462435
[TBL] [Abstract][Full Text] [Related]
8. Novel Therapeutics in Acute Myeloid Leukemia.
DiNardo CD; Stone RM; Medeiros BC
Am Soc Clin Oncol Educ Book; 2017; 37():495-503. PubMed ID: 28561688
[TBL] [Abstract][Full Text] [Related]
9. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.
Stuani L; Sabatier M; Saland E; Cognet G; Poupin N; Bosc C; Castelli FA; Gales L; Turtoi E; Montersino C; Farge T; Boet E; Broin N; Larrue C; Baran N; Cissé MY; Conti M; Loric S; Kaoma T; Hucteau A; Zavoriti A; Sahal A; Mouchel PL; Gotanègre M; Cassan C; Fernando L; Wang F; Hosseini M; Chu-Van E; Le Cam L; Carroll M; Selak MA; Vey N; Castellano R; Fenaille F; Turtoi A; Cazals G; Bories P; Gibon Y; Nicolay B; Ronseaux S; Marszalek JR; Takahashi K; DiNardo CD; Konopleva M; Pancaldi V; Collette Y; Bellvert F; Jourdan F; Linares LK; Récher C; Portais JC; Sarry JE
J Exp Med; 2021 May; 218(5):. PubMed ID: 33760042
[TBL] [Abstract][Full Text] [Related]
11. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
Tabata MM; Chase M; Kwong BY; Novoa RA; Fernandez-Pol S
J Cutan Pathol; 2020 Nov; 47(11):1042-1045. PubMed ID: 32588467
[TBL] [Abstract][Full Text] [Related]
12. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
DiNardo CD; Stein EM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
[TBL] [Abstract][Full Text] [Related]
13. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
Upadhyay VA; Brunner AM; Fathi AT
Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
[TBL] [Abstract][Full Text] [Related]
14. [Research advances of IDH gene mutation and AML].
Sun MD; Zheng YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1485-9. PubMed ID: 25338613
[TBL] [Abstract][Full Text] [Related]
15. Enasidenib.
Krämer A; Bochtler T
Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of isocitrate dehydrogenase mutant AML.
Boddu P; Borthakur G
Expert Opin Investig Drugs; 2017 May; 26(5):525-530. PubMed ID: 28388242
[No Abstract] [Full Text] [Related]
17. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
18. Ivosidenib Deemed Safe, Effective in AML.
Cancer Discov; 2018 Aug; 8(8):OF1. PubMed ID: 29934313
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.
Aiman W; Ali MA; Basit MA; Omar Z; Suleman M; Hassan M; Jamil T; Anwar MS; Shafique Z; Dhanesar G; Faisal MS; Akerman MJ; Maroules M; Anwer F
Leuk Res; 2023 Jun; 129():107077. PubMed ID: 37100025
[TBL] [Abstract][Full Text] [Related]
20. Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations.
Galeotti J; Coombs CC
Br J Haematol; 2019 Feb; 184(4):496. PubMed ID: 30334576
[No Abstract] [Full Text] [Related]
[Next] [New Search]
